Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

benralizumab depletes eosinophils directly, and our studies show that eosinophil counts were nearly completely depleted by week 4 of treatment," he said. This new mechanism of action addresses ...

Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.

“Based on [benralizumab’s] eosinophil-depleting mechanism of action, we’re hopeful it can help address these unmet needs and improve patient outcomes,” said Mene Pangalos, Executive Vice ...

Treatment with benralizumab was associated with statistically ... “The OSTRO results show that Fasenra’s eosinophil-depleting mechanism of action may benefit patients with this often ...

Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. We conducted a multicenter, double-blind, phase 3 ...

Patients on benralizumab had more significant change ... of disease suggest involvement of an additional pathogenic mechanism. “Previous studies of eosinophilic gastrointestinal diseases have ...

Benralizumab, a monoclonal antibody, has been shown to decrease the number of blood and sputum eosinophils. In this trial of 101 patients with COPD whether benralizumab reduces the number of acute ...

“The pathophysiology of CSU is complex, and the interplay of various cell types and molecular mechanisms defines the immune response of CSU.” Despite blood eosinophils depletion, benralizumab ...

Patients treated with benralizumab were more than four times ... This is likely due to its unique mechanism of action of inhibiting the receptor for interleukin-5 and potentially depleting blood ...

Moreover, the biologics that are available have different mechanisms of action, which make it challenging ... omalizumab, benralizumab, or mepolizumab for asthma between November 2018 and ...